Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072Source: DataRank Database

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.68)OA: bronzeTopics (31)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (31)

Anna Mrukwa ORCID,Christina Yau ORCID,Denise M. Wolf ORCID,Y.-Y. Chen,Ronald Balassanian ORCID

Live enrichment

PubMed:35513244 OpenAlex:https://openalex.org/W4225282825

Center for Biomedical Informatics and Information Technology, National Cancer Institute

Grant: 28XS197

Gateway for Cancer Research

Grant: G-16-900

Breast Cancer Research Foundation

Grant: AWDR11559

FWCI

1.68

Citation Percentile

0.9%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.annalsofoncology.org/article/S0923753422007621/pdf

BRONZEhttps://doi.org/10.1016/j.annonc.2022.04.072

publisherhttp://www.annalsofoncology.org/article/S0923753422007621/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0923753422007621?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0923753422007621?httpAccept=text/plain

Fields of Study

Breast Cancer Treatment StudiesGlobal Cancer Incidence and ScreeningCancer Risks and FactorsMedicineAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansNeoadjuvant TherapyNeoplasm, ResidualTreatment Outcome

MeSH Terms

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansTreatment OutcomeNeoplasm, ResidualNeoadjuvant Therapy

Keywords

MedicineBreast cancerRandomized controlled trialOncologyCancerChemotherapyNeoadjuvant therapyInternal medicineMetric (unit)Neoadjuvant chemotherapyResidual Cancer Burden

Sustainable Development Goals

SDG 0: Good health and well-being